

References

S-137

1. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Non-small cell lung cancer. Version 5.2021.
2. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Thyroid Carcinoma. Version 3.2021.
3. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology Pancreatic Adenocarcinoma. Version 2.2021.
4. Oc Y, Kilinc BE, Cennet S, et. al. Complications of computer tomography assisted radiofrequency ablation in the treatment of osteoid osteoma. *BioMed Res Int*. 2019;1-6.
5. National Institute for Health and Care Excellence (NICE). Percutaneous radiofrequency ablation of renal cancer. 2010.
6. Rosian K, Hawlik K, Piso B. Efficacy assessment of radiofrequency ablation as a palliative pain treatment in patients with painful metastatic spinal lesions: A systematic review. *Pain Physician*. 2018;21(5):E467-E476.
7. Albisinni U, Facchini G, Spinnato P, et al. Spinal osteoid osteoma: Efficacy and safety of radiofrequency ablation. *Skeletal Radiol*. 2017;46(8):1087-1094.
8. Lassalle L, Campagna R, Corcos G, et al. Therapeutic outcome of CT-guided radiofrequency ablation in patients with osteoid osteoma. *Skeletal Radiol*. 2017;46(7):949-956.
9. Peek MC, Ahmed M, Napoli A, et al. Minimally invasive ablative techniques in the treatment of breast cancer: A systematic review and meta-analysis. *Int J Hyperthermia*. 2016;33(2):1-12.
10. Tordjman M, Perronne L, Madelin G, Mali RD, et al. CT-guided radiofrequency ablation for osteoid osteomas: A systematic review. *Eur Radiol*. 2020;30(11):5952-5963.
11. Sahin C, Oc Y, Ediz N, Altınay M, et al. The safety and the efficacy of computed tomography guided percutaneous radiofrequency ablation of osteoid osteoma. *Acta Orthop Traumatol Turc*. 2019;53(5):360-365.

12. Hasegawa T, Takaki H, Kodama H, Yamanaka T, et al. Three-year survival rate after radiofrequency ablation for surgically resectable colorectal lung metastases: A prospective multicenter study. 2020;294(3):686-695.
13. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Head and Neck Cancer. Version 3.2021.
14. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Ovarian Cancer. Version 2.2021.
15. Barthet M, Giovannini M, Lesavre N, Boustiere C, et al. Endoscopic ultrasound-guided radiofrequency ablation for pancreatic neuroendocrine tumors and pancreatic cystic neoplasms: A prospective multicenter study. 2019;51(9):836-842.
16. Hlavsa J, Procházka V, Andrasina T, Pavlík T, et al. Radiofrequency ablation in pancreatic cancer. *Rozhl Chir.* 2019;98(11):441-449.
17. Oh D, Ko SW, Seo DW, Hong SM, et al. Endoscopic ultrasound-guided radiofrequency ablation of pancreatic microcystic serous cystic neoplasms: A retrospective study. 2021;53(7):739-743.
18. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Kidney Cancer. Version 1.2022.
19. InterQual® Level of Care Criteria 2021. Acute Care Adult. McKesson Health Solutions, LLC.
20. Dai Y, Covarrubias D, Uppot R, Arelleno RS. Image-guided percutaneous radiofrequency ablation of central renal cell carcinoma: Assessment of clinical efficacy and safety in 31 tumors. *J Vasc Interv Radiol.* 2017;28(12):1643-1650.
21. Dvorak P, Hoffmann P, Brodak M, Kosina J, Pacovsky J, et al. Percutaneous radiofrequency and microwave ablation in the treatment of renal tumors - 10 years of experience. *Wideochir Inne Tech Maloinwazyjne.* 2017;12(4):394-402.
22. Park BK, Gong IH, Kang MY, Sung HH, Jeon HG, et al. RFA versus robotic partial nephrectomy for T1a renal cell carcinoma: A propensity score-matched comparison of mid-term outcome. *Eur Radiol.* 2018;28(7):2979-2985.

23. Uhlig J, Strauss A, Rucker G, Seif Amir Hosseini A, et al. Partial nephrectomy versus ablative techniques for small renal masses: A systematic review and network meta-analysis. *Eur Radiol.* 2019;29(3):1293-1307.
24. Pessoa RR, Autorino R, Laguna MP, et al. Laparoscopic verses percutaneous cryoablation of small renal mass: Systematic review and cumulative analysis of comparative studies. *Clin Genitourin Cancer.* 2017;15(5):513-519.e5.
25. Campbell S, Uzzo RG, Allaf ME, et al. Renal mass and localized renal cancer: AUA Guideline. *J Urol.* 2017;198(3):520-529.
26. Marshall HR, Shakeri S, Hosseiny M, Sisk A, et al. Long-term survival after percutaneous radiofrequency ablation of pathologically proven renal cell carcinoma in 100 patients. *J Vasc Interv Radiol.* 2020;31(1):15-24.
27. Andrews JR, Atwell T, Schmit G, Lohse CM, et al. Oncologic outcomes following partial nephrectomy and percutaneous ablation for cT1 renal masses. *Eur Urol.* 2019;76(2):244-251.
28. Miyazaki M, Saito K, Yanagawa T, Chikuda H, et al. Phase I clinical trial of percutaneous cryoablation for osteoid osteoma. *Jpn J Radiol.* 2018;36(11):669-675.
29. Ierardi AM, Carnevale A, Angileri SA, Pellegrino F, et al Outcomes following minimally invasive image-guided percutaneous ablation of adrenal glands. *Gland Surg.* 2020;9(3):859-866.
30. Coupal TM, Pennycooke K, Mallinson PI, Ouellette HA, et al. The hopeless case? Palliative cryoablation and cementoplasty procedures for palliation of large pelvic bone metastases. *Pain Physician.* 2017;20(7):E1053-E1061.
31. Colangeli S, Parchi P, Andreani L, Beltrami G, et al. Cryotherapy efficacy and safety as local therapy in surgical treatment of musculoskeletal tumours. A retrospective case series of 143 patients. *J Biol Regul Homeost Agents.* 2018;32(6 Suppl. 1):65-70.
32. Yan S, Yang W, Zhu CM, Yan PM, et al. Comparison among cryoablation, radiofrequency ablation, and partial nephrectomy for renal cell carcinomas sized smaller than 2 cm or sized 2-4 cm: A population-based study. *Medicine (Baltimore).* 2019;98(21):e15610.

33. Morkos J, Porosnicu Rodriguez KA, Zhou A, Kolarich AR, et al. Percutaneous cryoablation for stage 1 renal cell carcinoma: Outcomes from a 10-year prospective study and comparison with matched cohorts from the National Cancer database. 2020;296(2):452-459.
34. Stacul F, Sachs C, Giudici F, Bertolotto M, et al. Cryoablation of renal tumors: Long-term follow-up from a multicenter experience. *Abdom Radiol (NY)*. 2021;46(9):4476-4488.
35. Callstrom MR, Woodrum DA, Nichols FC, Palussiere J, et al. Multicenter study of metastatic lung tumors targeted by interventional cryoablation evaluation (SOLSTICE). *J Thorac Oncol*. 2020;15(7):1200-1209.
36. Takada M, Toi M. Cryosurgery for primary breast cancers, its biological impact, and clinical outcomes. *Int J Clin Oncol*. 2019;24(6):608-613.
37. Fine RE, Gilmore RC, Dietz JR, Boolbol SK, et al. Cryoablation without excision for low-risk early-stage breast cancer: 3-Year interim analysis of ipsilateral breast tumor recurrence in the ICE3 trial. *Ann Surg Oncol*.
38. Wu Y, Gu Y, Zhang B, Zhou X, et al. Laparoscopic ultrasonography-guided cryoablation of locally advanced pancreatic cancer: A preliminary report. *Jpn J Radiol*.
39. He L, Niu L, Korpan NN, Sumida S, et al. Clinical practice guidelines for cryosurgery of pancreatic cancer: A consensus statement from the China Cooperative Group of Cryosurgery on Pancreatic Cancer, International Society of Cryosurgery, and Asian Society of Cryosurgery. 2017;46(8):967-972.
40. Jennings JW, Prologo JD, Garnon J, Gangi A, et al. Cryoablation for palliation of painful bone metastases: The MOTION multicenter study. *Radiol Imaging Cancer*. 2021;3(2):e200101.
41. Ferrer-Mileo L, Luque Blanco AI, González-Barboteo J. Efficacy of cryoablation to control cancer pain: A systematic review. *Pain Pract*. 2018;18(8):1083-1098.
42. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Bone Cancer. Version 1.2022.
43. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Breast Cancer. Version 1.2022.

44. Hayes, Inc. Hayes Health Technology Assessment. *Radiofrequency Ablation for Benign Thyroid Nodules*. Lansdale, PA: Hayes, Inc.; 06/29/2021.